$19.59
0.86%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US86150R1077
Symbol
STOK

Stoke Therapeutics Inc Stock price

$19.59
+6.45 49.09% 1M
+12.19 164.73% 6M
+8.56 77.61% YTD
+5.04 34.64% 1Y
+4.41 29.05% 3Y
-8.98 31.43% 5Y
+1.59 8.83% 10Y
+1.59 8.83% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.17 0.86%
ISIN
US86150R1077
Symbol
STOK
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$825.8m
Net debt
positive
Cash
$247.7m
Shares outstanding
54.7m
Valuation (TTM | estimate)
P/E
22.0 | 64.2
P/S
5.4 | 5.7
EV/Sales
4.1 | 4.4
EV/FCF
13.5
P/B
3.2
Financial Health
Equity Ratio
84.3%
Return on Equity
-38.9%
ROCE
11.7%
ROIC
32.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$199.9m | $188.5m
EBITDA
$42.3m | $-932.8k
EBIT
$40.3m | $-20.7m
Net Income
$52.5m | $16.7m
Free Cash Flow
$61.2m
Growth (TTM | estimate)
Revenue
1,218.5% | 415.5%
EBITDA
137.7% | 99.1%
EBIT
135.2% | 79.6%
Net Income
150.7% | 118.8%
Free Cash Flow
175.9%
Margin (TTM | estimate)
Gross
-
EBITDA
21.2% | -0.5%
EBIT
20.2%
Net
26.3% | 8.9%
Free Cash Flow
30.6%
More
EPS
$0.9
FCF per Share
$1.1
Short interest
24.7%
Employees
128
Rev per Employee
$290.0k
Show more

Is Stoke Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Stoke Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Stoke Therapeutics Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Stoke Therapeutics Inc forecast:

Buy
88%
Hold
12%

Financial data from Stoke Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
200 200
1,219% 1,219%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 55 55
26% 26%
28%
- Research and Development Expense 104 104
22% 22%
52%
42 42
138% 138%
21%
- Depreciation and Amortization 1.99 1.99
16% 16%
1%
EBIT (Operating Income) EBIT 40 40
135% 135%
20%
Net Profit 52 52
151% 151%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Stoke Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stoke Therapeutics Inc Stock News

Neutral
Business Wire
one day ago
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first ...
Neutral
Business Wire
6 days ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Execut...
Neutral
Business Wire
9 days ago
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress (IEC), taking place August 3...
More Stoke Therapeutics Inc News

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Head office United States
CEO Ian Smith
Employees 128
Founded 2014
Website www.stoketherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today